Ann: Race Leadership Changes, page-286

Some thoughts:

1. Certainly disappointing to see DT step down, comforting to know he is still heavily invested and maintains a strong position in the ranks of shareholders. Should be interesting to see if this changes his communication on the company.

2. Interesting to see who / how the quality of announcements will be from now on.

3. While taken with a grain of salt, some reasonable assumptions as to the reasoning for departure are made within the thread - still feels a bit left of field.

On the discussion of timing, the implication being an offer/partnership/licensing agreement now more imminent as the catalyst, is that really likely since we haven't even received the IV formulation yet, to even commence trials with Zantrene for cardio protection?

4. Also, is there any concerns around these discussions occurring without a full time CSO and CMO, what is the issue with replacing the CMO? Perhaps now it's easier is the focus is cardio protection (allegedly) rather than FTO

Finally, it would be disappointing to see the Board effectively push DT out in order to push for a transaction on cardio protection quickly and effectively bed FTO indefinitely. Surely a structure could exist to retain IP and allow FTO to be explored and confirmed over then 3-5 years, financed on the back of a successful cardioprotect transaction, in whatever to form that takes?

Interesting times, the ground work is there now the remaining Board have to deliver.